牛牛AI助手已提取核心信息
On January 26, 2024, Evelo Biosciences, Inc. held a special meeting of stockholders where two key proposals were voted upon. The first proposal, which passed with 11,168,514 votes for, 222,299 against, and 7,940 abstained, was the approval of the liquidation and dissolution of the company and the Plan of Liquidation and Dissolution. The second proposal, which also passed, granted discretionary authority to adjourn the special meeting to solicit additional proxies if necessary. However, adjournment was not required as the first proposal received sufficient votes for approval. The Board of Directors now has the authority to proceed with the dissolution but retains the discretion to decide the timing and whether to move forward with or abandon the dissolution, or to amend the plan as permitted by Delaware law without further stockholder approval. This follows the delisting of Evelo Biosciences' shares from Nasdaq, as reported in a previous Form 8-K filed on November 21, 2023.
On January 26, 2024, Evelo Biosciences, Inc. held a special meeting of stockholders where two key proposals were voted upon. The first proposal, which passed with 11,168,514 votes for, 222,299 against, and 7,940 abstained, was the approval of the liquidation and dissolution of the company and the Plan of Liquidation and Dissolution. The second proposal, which also passed, granted discretionary authority to adjourn the special meeting to solicit additional proxies if necessary. However, adjournment was not required as the first proposal received sufficient votes for approval. The Board of Directors now has the authority to proceed with the dissolution but retains the discretion to decide the timing and whether to move forward with or abandon the dissolution, or to amend the plan as permitted by Delaware law without further stockholder approval. This follows the delisting of Evelo Biosciences' shares from Nasdaq, as reported in a previous Form 8-K filed on November 21, 2023.
2024年1月26日，Evelo Biosciences, Inc.举行了一次股东特别会议，对两项关键提案进行了表决。第一项提案以11,168,514票赞成、222,299票反对、7,940票弃权获得通过，是批准公司的清算和解散以及清算和解散计划。第二项提案也获得通过，授权酌情宣布特别会议休会，以便在必要时征集更多代理人。但是，由于第一项提案获得了足够的票数可供批准，因此不需要休会。董事会现在有权着手解散，但保留决定时机以及推进还是放弃解散的自由裁量权，或者在未经股东进一步批准的情况下根据特拉华州法律允许修改计划的自由裁量权。在此之前，正如2023年11月21日提交的8-K表格所报告的那样，Evelo Biosciences的股票已从纳斯达克退市。
2024年1月26日，Evelo Biosciences, Inc.举行了一次股东特别会议，对两项关键提案进行了表决。第一项提案以11,168,514票赞成、222,299票反对、7,940票弃权获得通过，是批准公司的清算和解散以及清算和解散计划。第二项提案也获得通过，授权酌情宣布特别会议休会，以便在必要时征集更多代理人。但是，由于第一项提案获得了足够的票数可供批准，因此不需要休会。董事会现在有权着手解散，但保留决定时机以及推进还是放弃解散的自由裁量权，或者在未经股东进一步批准的情况下根据特拉华州法律允许修改计划的自由裁量权。在此之前，正如2023年11月21日提交的8-K表格所报告的那样，Evelo Biosciences的股票已从纳斯达克退市。
有用
没用